⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LXRX News
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
globenewswire.com
LXRX
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
prnewswire.com
MLYS
PROK
IRON
REGN
AMGN
MAZE
LLY
JNJ
LXRX
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
globenewswire.com
LXRX
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
globenewswire.com
LXRX
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
globenewswire.com
LXRX
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
globenewswire.com
LXRX
Lexicon Announces Proposed Public Offering of Common Stock
globenewswire.com
LXRX
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
globenewswire.com
LXRX
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
globenewswire.com
LXRX
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY